ReviewIJID regions2025
Acute gastroenteritis in Trinidad and Tobago: identifying trend by season, geography, and demographics from 2006 to 2023.
Review in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Acute gastroenteritis (AGE) remains a major public health and economic concern globally, including in Trinidad and Tobago, where one in ten residents is affected annually. Therefore, this study aimed to assess, for the first time, AGE trends from 2006 to 2023, focusing on demographic, seasonal, and geographic factors to guide targeted public health strategies. Methods: AGE surveillance data from 2006 to 2023, comprising all individuals presenting to any public healthcare facility in Trinidad and Tobago with AGE (defined as more than three watery stools within 24 hours), were obtained from the National Epidemiology Unit. Data were managed in Microsoft Excel and analyzed using Genstat 19 and Joinpoint Regression Program. Background characteristics were summarized descriptively using mean (SD) and frequencies. Trend analysis was performed while accounting for age group, month, year, season, and county to evaluate temporal and spatial variations in AGE incidence. Results: Between 2006 and 2023, a total of 353,269 AGE-related healthcare visits were recorded, with the highest burden in 2010 and the lowest in 2022. Overall, AGE incidence followed four phases: a decline (2006-2015, annual percent change [APC] -2.26, 95% confidence interval [CI]), an increase (2015-2018, APC 5.84, 95% CI), a sharp decline (2018-2021, APC -36.07, 95% CI), and a rebound increase (2021-2023, APC 43.26, 95% CI). By age group, AGE incidence declined in children under 5 years between 2010 and 2018 (APC -51.04, 95% CI), while in individuals aged 5 years and older, it decreased slightly from 2006 to 2015 (APC -1.11, 95% CI). Analysis by season showed different trends: in the dry season, there was an increase from 2015 to 2018 (APC 66.73, 95% CI), while in the wet season, there was a decrease from 2010 to 2018 (APC -24.00, 95% CI). Both wet and dry seasons also exhibited sharp declines during 2018-2021. Residents within the counties of Nariva, St. Patrick, Victoria, and Caroni recorded higher AGE incidence compared to other counties. Conclusions: The findings indicate higher AGE burdens across specific counties, variations in incidence between wet and dry seasons, and differences among age groups over the period 2006-2023, highlighting the need for age- and region-specific interventions, particularly in rural areas and during high-risk seasons. These results underscore the importance of enhanced AGE surveillance and the implementation of targeted public health measures in Trinidad and Tobago.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.